This is an old revision of the document!


McGill Interdisciplinary Initiative in Infection and Immunity

The McGill Interdisciplinary Initiative in Infection and Immunity (MI4) is a Canadian research organization in Montreal, Quebec. It is based out of McGill University.

History

COVID-19

MI4 provided research funding related to COVID-19 through their “MI4 Emergency COVID-19 Research Funding” program.1) In particular, MI4 participated as a funding partner of the Canadian arm of the first randomized control trial (RCT) testing hydroxychloroquine for the post-exposure prevention of COVID-19, which began on March 17, 2020.2)

Organization

Partners

Funding

MI4 received funding for their “MI4 Emergency COVID-19 Research Funding” program through the McGill University Health Centre Foundation COVID-19 Emergency Fund from:4)

1) , 4)
Results of MI4 Emergency COVID-19 Research Funding. MI4. Retrieved May 16, 2023, from https://web.archive.org/web/20230516234033/https://www.mcgill.ca/mi4/mi4-supported-research/emergency-covid-19-research-funding
2)
Lofgren, S. M., Nicol, M. R., Bangdiwala, A. S., Pastick, K. A., Okafor, E. C., Skipper, C. P., Pullen, M. F., Engen, N., Abassi, M., Williams, D. A., Nascene, A. A., Axelrod, M. L., Lother, S. A., MacKenzie, L. J., Drobot, G., Marten, N., Cheng, M. P., Zarychanshi, R., Schwartz, I. S., & Silverman, M. J. (2020). Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19. medRxiv. https://doi.org/10.1101/2020.07.16.20155531
Back to top